(Sharecast News) - Novartis shares were sliding on Tuesday morning, after it reported solid third-quarter revenue growth but missed earnings expectations as the loss of patent protection for its blockbuster heart drug Entresto weighed on margins.
The Swiss pharmaceutical group said net income rose 23% to $3.93bn on sales of $13.91bn,...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE